What Is Behind the Oneview Healthcare (ASX:ONE) Share Price Fall of 13%?

Sonal Goyal

22 October 2026 05:52 PM AEDT

What Is Behind the Oneview Healthcare (ASX:ONE) Share Price Fall of 13%?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Oneview Healthcare shares were down 13.04% at $0.10 during the Trading session on 22 October 2026
Recurring revenue rose 13% to EUR 4.3 million in the six months to 30 June 2026, while total revenue fell 14% to EUR 5.5 million
An A$7 million second Placement Tranche remains subject to Shareholder approval, which the company expects to seek at its AGM in the fourth quarter of 2026

Shares in Oneview Healthcare PLC (ASX:ONE) were down 13.04% at $0.10 during the trading session on 22 October 2026, at the time of the data. The S&P/ASX 200 stood at 8,792.20, down 0.44%, while the All Ordinaries stood at 8,916.20, down 0.45%. Oneview develops software for the healthcare sector, and in its half-year report for the six months ended 30 June 2026, with directors' approval dated 26 August 2026, it reported higher Recurring Revenue and a narrower loss.

About the Company

Oneview Healthcare PLC is listed on the Australian Securities Exchange under the ticker ONE and is domiciled in Ireland, with its registered office in Blackrock, Co. Dublin. It also has an office in Victoria, Australia.

The company listed in Australia through an initial public offering in March 2016 and has financed its operations through the sale of Equity securities. It reports in euros and had 839,193,060 securities on issue at 30 June 2026.

Business Overview

The principal activity of the group is the development and sale of software for the healthcare sector, along with associated hardware and related consultancy services. It has customers in the USA, Ireland, Thailand and Australia.

At 30 June 2026 the Oneview system was live in 15,092 endpoints, compared with 14,880 at 31 December 2025. The 1% net increase reflects the deployment of 693 units across customer sites, partly offset by the decommissioning of 481 endpoints at an Australian customer. Average headcount was 90 employees.

Half-Year Financial Results

In its half-year report dated 26 August 2026, Oneview reported total revenue of EUR 5,484,844, down 14% from EUR 6,341,970. Recurring revenue increased 13% to EUR 4,312,516, while non-recurring revenue fell 54% to EUR 1,172,328, which the company attributed mainly to one-off hardware sales in the comparative period and lower deployment activity.

Gross Margin rose to 70% from 61%, leaving Gross Profit stable at EUR 3.8 million. Cash operating expenses decreased 6% to EUR 7.8 million, mainly on lower employee costs after a June 2025 workforce restructuring. The loss after tax attributable to members was EUR 5,493,233, down from EUR 7,888,504, and net tangible assets per security were EUR 0.007. No Dividend was declared.

Commercial Initiatives

In May 2026, Oneview launched Bedside Hub, a channel for delivering Epic MyChart Bedside TV on healthcare-grade hardware with cloud-based device management, following certification by Epic. The company said it is engaging with a growing number of health systems and is targeting the addition of several new Bedside Hub customers during the second half of 2026.

The company was also added to a National Care Communication Agreement between Baxter and the purchasing organisation of one of the ten largest health systems in the United States. It expects to begin initial projects in the second half of 2026, with potential for deployment across a network of more than 85 hospitals and about 15,000 beds.

Funding and Going Concern

The group had cash of EUR 7.2 million at 30 June 2026. In March 2026 it secured a two-tranche institutional placement raising A$19 million in gross proceeds. Tranche 1, of A$12 million, settled on 24 March 2026, while Tranche 2, of A$7 million from significant shareholder Manderrah Pty Ltd, remains subject to shareholder approval. The directors adopted the Going Concern basis, and the interim statements were reviewed by KPMG.

Related Sector Context

Healthcare technology companies Supply software and connected hardware to hospitals and health systems, where purchasing cycles can be lengthy and deployments are often staged across sites. Smaller listed MedTech names can see sizeable share price moves on limited trading volumes.

During the 22 October 2026 session, the S&P/ASX 200 was down 0.44% and the All Ordinaries down 0.45%, while Oneview shares were down 13.04% at the time of the data.

Risks to Weigh In

The group has incurred net losses and negative operating cash flows since inception. Tranche 2 of the placement depends on shareholder approval, and the directors' going concern assessment also noted the inherent uncertainty around the timing and conversion of sales opportunities and revenue growth assumptions.

Total revenue declined 14% in the period, and endpoint numbers were affected by the decommissioning of 481 endpoints at an Australian customer. The Bedside Hub and Baxter agreement initiatives are at an early commercial stage, with outcomes dependent on customer decisions.

Catalysts on Watch

The company expects to seek shareholder approval for Tranche 2 at its Annual General Meeting in the fourth quarter of 2026. It is also targeting new Bedside Hub customers and the start of initial projects under the Baxter agreement during the second half of 2026.

Putting It Together

Oneview Healthcare shares were down 13.04% at $0.10 during the 22 October 2026 session, while the S&P/ASX 200 and All Ordinaries each eased by less than half a percent. The half-year report dated 26 August 2026 showed recurring revenue of EUR 4.3 million, a 70% gross margin and a loss of EUR 5.5 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.